Defense firm Anduril says U.S. delay on Taiwan arms sales affecting its business

Anduril founder Palmer Luckey said President Trump's months-long delay in approving a $14 billion Taiwan arms package is impairing Anduril's Taiwan business and slowing related defense-procurement progress. Trump has held the sale in abeyance following a May meeting with China's Xi Jinping, treating it as leverage ahead of their Washington meeting next week. The decision reflects U.S. concerns that expanded arms sales could prompt Chinese retaliation, including restrictions involving rare earths critical to U.S. technology companies.

Analysis

The immediate public-equity implication is weaker than the geopolitical headline suggests: Anduril is private, and the composition of the stalled procurement is the critical missing variable. A release weighted toward autonomous systems would validate demand and pricing for AVAV, KTOS and RCAT; a release dominated by conventional munitions, air defense or sustainment would instead accrue to LMT, RTX and NOC. Until line items, production milestones and funding terms are disclosed, treating the event as a broad defense-sector catalyst risks buying backlog that may not belong to listed peers.

The more investable mechanism is the policy linkage between Taiwan security assistance and Chinese leverage over critical-material supply chains. Any near-term accommodation that preserves consumer-tech inputs may cap the geopolitical premium in TSM and the semiconductor complex, but it leaves a structural incentive for Pentagon procurement and domestic sourcing of drones, propulsion, sensors and rare earths. Over 6-18 months, this favors US-controlled defense supply chains and MP, though MP remains highly sensitive to realized NdPr pricing, offtake execution and government support rather than rhetoric.

A delayed decision is not necessarily bearish for defense demand; it shifts revenue recognition and can create a larger eventual authorization once negotiations conclude. The contrarian risk is that investors overprice a near-term approval after the summit: an explicit linkage of arms sales to bilateral concessions would increase the probability of future stop-start procurement, raising working-capital, inventory and delivery-risk discounts for smaller drone suppliers. The thesis is falsified if the eventual package excludes autonomous systems, if Taiwan funding is deferred, or if China material restrictions fail to tighten and rare-earth prices remain depressed.

Key Decisions for Investors

• Do not add broad XAR/ITA exposure solely on this development. Set an alert for the authorization notice and procurement annex; initiate a 1-3 month long AVAV/KTOS basket only if autonomous-drone and loitering-munition awards are specified, with a 7-10% stop because neither company has disclosed sufficient Taiwan revenue to underwrite a pre-event trade.
• Maintain a modest 6-12 month long MP as a policy-supply-chain hedge, sized for high commodity volatility. Add only on confirmation of tighter Chinese export restrictions or a binding domestic/offtake catalyst; exit if NdPr pricing and realized margins do not improve through the next two reporting periods.
• For event-risk protection around the bilateral meeting, buy 1-2 month TSM put spreads rather than shorting semiconductors outright. The payoff is asymmetric if Taiwan becomes an explicit negotiating variable or China signals retaliatory trade measures; close the hedge if a clear arms approval and de-escalatory materials language emerge.
• If the package is approved with meaningful missile and air-defense content but limited drone content, rotate the prospective drone basket into LMT/RTX rather than chasing AVAV or KTOS; this outcome would monetize established production capacity, while private Anduril remains the more direct autonomous-systems beneficiary.